Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Apalutamide + 89Sr Neoadjuvant Therapy in Prostate Cancer
NCT05740488Recruiting
- Sponsor
- Southern Medical University Zhujiang Hospital
- Start
- Jan 2022
- Primary completion
- Apr 2025
- Modality
- Orthosteric Ligands
- Countries
- 1
01
Overview
Open-label, single-arm trial of apalutamide in prostate cancer (PCa), sponsored by Southern Medical University Zhujiang Hospital. Primary endpoint: Progression-Free Survival at 2 years. Started Jan 2022; status: recruiting.
02
Drugs
apalutamide
03
Conditions
prostate cancer (PCa)
Beyond the preview
Go deeper on NCT05740488.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05740488.